Complications with the use of botulinum toxin

International Ophthalmology Clinics

Volumn 45, Issue 3, 2005, Pages 163-169

  Klein, Arnold William ^a  

^a 435 N Roxbury Drive ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B;

BOTULISM; CROW FEET; DIPLOPIA; DRUG CONTRAINDICATION; DRUG INDICATION; DRUG RESISTANCE; DRY EYE; ECCHYMOSIS; ECTROPION; EDEMA; ERYTHEMA; ESTHETICS; EXOPHTHALMOS; EYEBROW; FACE; FACE MUSCLE; FATIGUE; FOREHEAD; FRONTALIS MUSCLE; GLABELLA; HEADACHE; HUMAN; HYPESTHESIA; IATROGENIC DISEASE; INFORMED CONSENT; MALAISE; MUSCLE WEAKNESS; NASOLABIAL FOLD; NAUSEA; NECK; NEUROTOXICITY; ORBICULARIS OCULI MUSCLE; PAIN; PRIORITY JOURNAL; PTOSIS; RASH; REJUVENATION; REVIEW; SKIN; WRINKLE;

BOTULINUM TOXIN TYPE A; HUMANS; NEUROMUSCULAR AGENTS;

EID: 22544477590     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.iio.0000167239.34149.13     Document Type: Review

References (18)

1. Lamanns C. The most poisonous poison. Science. 1969;130:763-772.
2. Dertzbaugh MT, West MW. Mapping of protective and cross-reactive domains of the type A neurotoxin of Clostridium botulinum. Vaccine. 1996;16:1538-1544.
3. Somers E, DasGupta BR. Clostridium botulinum type A, B, C1 and E produce proteins with or without hemagglutinating activity: do they share common amino acid sequences and genes? J Protein Chem. 1991;10:415-425.
4. Sakaguchi G. Clostridium botulinum toxins. Pharmacol Ther. 1982;19:165-194.
5. Baffi RA, Garnick RL. Quality control issues in the analysis of lyophilized proteins. Dev Biol Stand. 1991;74:181-184.
6. Carruthers A, Carruthers J. Botulinum toxin type A: history and current cosmetic use in the upper face. Semin Cutan Med Surg. 2001;20:71-84.
7. BOTOX Cosmetic (botulinum toxin type A for injection) purified neurotoxin complex (product monograph). Markham, Ontario: Allergan Inc.; 2001.
8. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology. 1995;45:1743-1746.
9. Aoki R. Allergan, Inc.: Irvine, California, personal communication; 2002.
10. NIH. Clinical use of botulinum toxin. National Institutes of Health Consensus Development Conference, NIH Consensus Statement, November 12-14, 1990.
11. Borodic G, Johnson E, Goodnough M, et al. Botulinum toxin therapy, immunologic resistance and problems with available materials. Neurology. 1996;46:26-29.
12. Burns RL. Complications of botulinum exotoxin. Presented at the 25th Annual Clinical and Scientific Meeting of the ASDS, Portland, OR, May 1998.
13. Klein A. Cosmetic therapy with botulinum toxin: anecdotal memoirs. Dermatol Surg. 1996;22:757-759.
14. Foster JA, Barnhorst D, Papay F, et al. The use of botulinum A toxin to ameliorate facial kinetic frown lines. Ophthalmology. 1996;103:618-622.
15. Carruthers J, Carruthers A. BOTOX use in the mid and lower face and neck. Semin Cutan Med Surg. 2001;20:85-92.
16. Lowe NJ, Lask GL. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet. J Am Acad Dermatol. 2002;47:834-840.
17. Ludlow CL, Hallat M, Rhew K, et al. Therapeutic use of type F botulinum toxin [letter]. N Engl J Med. 1992;326:349-350.
18. Sankhla C, Sankovic J, Duane D. Variability of the immunologic and clinical response in dystonic patients immunoresistant to botulinum toxin injections. Mov Discord. 1998; 13:150-154.